Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
An anticancer drug developed by Sichuan Biokin Pharmaceutical doubled the lung cancer survival window in a phase 3 trial.
An anticancer drug developed by Sichuan Biokin Pharmaceutical doubled the lung cancer survival window in a phase 3 trial.